Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

Open access
Abdi, Jahangir, Chen, Guoan, Chang, Hong·2013·Oncotarget

Abstract

// Jahangir Abdi 1,2 , Guoan Chen 3 , Hong Chang 1,2,4 1 Division of Immunopharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 2 Dept. of Laboratory Hematology, University Health Network, Toronto, Ontario, Canada 3 Dept. of Hematology & Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China 4 Division of Molecular and Cellular Biology, Toronto General Research Institute; Toronto, Ontario, Canada Correspondence: Hong Chang, email: // Keywords : multiple myeloma, drug resistance, signaling pathways, oncogenes Received : October 13, 2013 Accepted : November 22, 2013 Published : November 24, 2013 Abstract In the era of new and mostly effective therapeutic protocols, multiple myeloma still tends to be a hard-to-treat hematologic cancer. This hallmark of the disease is in fact a sequel to drug resistant phenotypes persisting initially or emerging in the course of treatment. Furthermore, the heterogeneous nature of multiple myeloma makes treating patients with the same drug challenging because finding a drugable oncogenic process common to all patients is not yet feasible, while our current knowledge of genetic/epigenetic basis of multiple myeloma pathogenesis is outstanding. Nonetheless, bone marrow microenvironment components are well known as playing critical roles in myeloma tumor cell survival and environment-mediated drug resistance happening most possibly in all myeloma patients. Generally speaking, however; real mechanisms underlying drug resistance in multiple myeloma are not completely understood. The present review will discuss the latest findings and concepts in this regard. It reviews the association of important chromosomal translocations, oncogenes (e.g. TP53) mutations and deranged signaling pathways (e.g. NFκB) with drug response in clinical and experimental investigations. It will also highlight how bone marrow microenvironment signals (Wnt, Notch) and myeloma cancer stem cells could contribute to drug resistance in multiple myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1497

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 172

Metadata

Authors
Abdi, J., Chen, G., & Chang, H.
Venue
Oncotarget
Published
2013-11-24
Volume
4
Issue
12
Pages
2186-2207
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2103289668
Cited by
172
References
11
FWCI
10.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. https://app.cochat.ai/papers/10.18632/oncotarget.1497
The paper
Abdi, J., Chen, G., & Chang, H. (2013). Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. https://doi.org/10.18632/oncotarget.1497

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.